# Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

> **NCT02896101** · PHASE3 · COMPLETED · sponsor: **Glenmark Pharmaceuticals Ltd. India** · enrollment: 755 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Pimecrolimus Cream, 1%
- **DRUG:** Elidel® (pimecrolimus) Cream
- **DRUG:** Placebo of Pimecrolimus Cream, 1%

## Key facts

- **NCT ID:** NCT02896101
- **Lead sponsor:** Glenmark Pharmaceuticals Ltd. India
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 755 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02896101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02896101, "Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02896101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*